U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06792734) titled 'Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas' on Jan. 20.
Brief Summary: The goal of this clinical trial is to learn if BMT-3566 can safety be given to adult patients with relapsed or refractory mature b cell lymphomas. It will also learn how well BTM-3566 works to treat relapsed or refractory mature b cell lymphomas. The main questions it aims to answer are:
What are the side effects of BTM-3566 at different doses? What are the levels of BTM-3566 in the blood at different timepoints around dosing? What is the clinical benefit of BTM-3566 in treating cancer (i.e. how well does it slow or stop disease pro...